HBsAb且HBcAb阳性的非霍奇金淋巴瘤患者HBV再激活1例并文献复习

李卓, 李子坚, 马婷, 等. HBsAb且HBcAb阳性的非霍奇金淋巴瘤患者HBV再激活1例并文献复习[J]. 临床血液学杂志, 2016, 29(3): 237-239. doi: 10.13201/j.issn.1004-2806.2016.03.019
引用本文: 李卓, 李子坚, 马婷, 等. HBsAb且HBcAb阳性的非霍奇金淋巴瘤患者HBV再激活1例并文献复习[J]. 临床血液学杂志, 2016, 29(3): 237-239. doi: 10.13201/j.issn.1004-2806.2016.03.019
LI Zhuo, LI Zijian, MA Ting, et al. HBV reactivation in a HBsAb and HBcAb double positive non-Hodgkin's lymphoma patient:a case report and literature review[J]. J Clin Hematol, 2016, 29(3): 237-239. doi: 10.13201/j.issn.1004-2806.2016.03.019
Citation: LI Zhuo, LI Zijian, MA Ting, et al. HBV reactivation in a HBsAb and HBcAb double positive non-Hodgkin's lymphoma patient:a case report and literature review[J]. J Clin Hematol, 2016, 29(3): 237-239. doi: 10.13201/j.issn.1004-2806.2016.03.019

HBsAb且HBcAb阳性的非霍奇金淋巴瘤患者HBV再激活1例并文献复习

详细信息
    通讯作者: 席亚明,E-mail:xiyaming02@163.com
  • 中图分类号: R733.4

HBV reactivation in a HBsAb and HBcAb double positive non-Hodgkin's lymphoma patient:a case report and literature review

More Information
  • 加载中
  • [1]

    李兰娟,任红.传染病学[M].8版.北京:人民卫生出版社,2013:22-33.

    [2]

    Wang F,Xu RH,Han B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers[J].Cancer,2007,109:1360-1364.

    [3]

    Wang YH,Fan L,Wang L,et al.Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy[J].Support Care Cancer,2013,21:1265-1271.

    [4]

    中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会,中华医学会肝病学分会.中国淋巴瘤合并HBV感染患者管理专家共识[J].中华血液学杂志,2013,34(11):988-993.

    [5]

    Evens AM,Jovanovic BD,Su YC,et al.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases:meta-analysis and examination of FDA safety reports[J].Ann Oncol,2011,22:1170-1180.

    [6]

    Huang YH,Lin HC,Lee SD.Management of chemotherapy-induced hepatitis B virus reactivation[J].J Chin Med Assoc,2012,75:359-362.

    [7]

    Tsutsumi Y,Oqasawara R,Kamihara Y,et al.Rituximab administration and reactivation of HBV[J].Hepat Res Treat,2010,2010:1-8.

    [8]

    Sarrecchia C,Cappelli A,Aiello P.HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb[J].J Infec Chemother,2005,11:189-191.

    [9]

    中国临床肿瘤学会,中华医学会血液学分会,中国医师协会肿瘤医师考核委员会.淋巴瘤免疫化疗HBV预防和治疗中国专家共识[J].临床肿瘤学杂志,2013,18(10):935-941.

    [10]

    Zelenetz AD,Gordon LI,Wierda WG,et al.Chronic lymphocytic leukemia/small lymphocytic lymphoma,Version 1.2015[J].J Nati Compr Canc Netw,2015,13:326-362.

    [11]

    Xu L,Tu Z,Xu G,et al.Epirubicin directly promotes hepatitis B virus (HBV) replication in stable HBV-expressing cell lines:a novel mechanism of HBV reactivation following anticancer chemotherapy[J].Mol Med Rep,2014,9:1345-1350.

    [12]

    Salpini R,Colaqrossi L,Bellocchi MC,et al.Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression[J].Hepatology,2015,61:823-833.

    [13]

    Kim EB,Kim DS,Park SJ,et al.Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy[J].Cancer Res Treat,2008,40:36-38.

    [14]

    Hui CK,Cheung WW,Zhang HY,et al.Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy[J].Gastroenterology,2006,131:59-68.

  • 加载中
计量
  • 文章访问数:  216
  • PDF下载数:  134
  • 施引文献:  0
出版历程
收稿日期:  2015-06-27

目录